US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Valion Bio Inc

0.2970

+0.01103.85%

Post-market: 0.31000.0130+4.38%19:51 EDT

Volume:6.27M

Turnover:2.16M

Market Cap:1.23M

PE:-0.04

High:0.4290

Open:0.2800

Low:0.2700

Close:0.2860

52wk High:5.60

52wk Low:0.2531

Shares:4.15M

Float Shares:3.51M

Volume Ratio:5.80

T/O Rate:178.71%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-7.9962

EPS(LYR):-7.6830

ROE:-182.22%

ROA:-36.18%

PB:0.11

PE(LYR):-0.04

Loading ...

Overview Company News Filings

Ukraine Health Ministry Accepts Valion Bio Entolimod Dossier for Regulatory Review

Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

THOMSON REUTERS

Valion Bio - Formal Review of Entolimod in Ukraine May be Completed in 45 to 60 Days

THOMSON REUTERS

Valion Bio Notifies Availability of Press Release on Entolimod Trial at Sheba Medical Center

Valion Bio Advances Entolimod Program with Government Engagement, Manufacturing Scale-Up, Oncology Supportive Care Plans

MT Newswires Live

Valion Bio reports continued development of Entolimod program

Valion Bio Says Afrri, NIAID Design Murine Survival Protocol to Test Entolimod for Gi-ars

Afrri/niaid Designs Proprietary Pbi-bm2.5 Protocol to Evaluate Valion Bio's (nasdaq: Vbio) Entolimod as the First and Only Treatment for Gi-ars

THOMSON REUTERS

Valion Bio issues USD 250,000 Series B preferred shares, warrant to 3i in private placement

Valion Bio confirms House panel directive to prioritize radiation, nuclear countermeasures

Valion Bio briefs Department of War, BARDA officials on Entolimod for radiation syndrome

Valion Bio’s Velocity Bioworks licenses LarmorBio’s BioScan-NMR platform

Valion Bio Q1 net loss widens to $6.2 million

BRIEF-Valion Bio Reports First Quarter 2026 Financial Results

Valion Bio Q1 EPS $(2.23) Up From $(2.52) YoY

Valion Bio Inc - Q1 2026 Net Loss $2.23 per Share

THOMSON REUTERS

Valion Bio schedules first-quarter financial results release and conference call

Valion Bio subsidiary Velocity Bioworks opens biomanufacturing facility in San Antonio

Valion Bio receives first study protocol under agreement with NIAID

Valion Bio says NIAID funds up to $7 million Entolimod BLA-enabling studies under FDA Animal Rule

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/VBIO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VBIO\",,,,,undefined,":{"symbol":"VBIO","market":"US","secType":"STK","nameCN":"Valion Bio Inc","latestPrice":0.297,"timestamp":1784923200000,"preClose":0.286,"halted":0,"volume":6273843,"hourTrading":{"tag":"盘后","latestPrice":0.31,"preClose":0.297,"latestTime":"19:51 EDT","volume":680897,"amount":206573.124089,"timestamp":1784937103081,"change":0.013,"changeRate":0.043771,"amplitude":0.368687},"delay":0,"changeRate":0.0384615384615385,"floatShares":3510600,"shares":4151259,"eps":-7.996244,"marketStatus":"Market Closed","change":0.011,"latestTime":"07-24 16:00:00 EDT","open":0.28,"high":0.429,"low":0.27,"amount":2155091.92254804,"amplitude":0.555944,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-7.996244,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"listingDate":1636606800000,"exchange":"NASDAQ","adjPreClose":0.286,"preHourTrading":{"tag":"盘前","latestPrice":0.28,"preClose":0.286,"latestTime":"09:29 EDT","volume":8652,"amount":2484.7102576800003,"timestamp":1784899799999,"change":-0.006,"changeRate":-0.020979,"amplitude":0.079371},"postHourTrading":{"tag":"盘后","latestPrice":0.31,"preClose":0.297,"latestTime":"19:51 EDT","volume":680897,"amount":206573.124089,"timestamp":1784937103081,"change":0.013,"changeRate":0.043771,"amplitude":0.368687},"volumeRatio":5.797481671719668},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VBIO\",,,,,undefined,":{"symbol":"VBIO","floatShares":3510600,"roa":"-36.18%","roe":"-182.22%","lyrEps":-7.683047,"volumeRatio":5.797481671719668,"shares":4151259,"dividePrice":0,"high":0.429,"amplitude":0.555944,"preClose":0.286,"low":0.27,"week52Low":0.2531,"pbRate":"0.11","week52High":5.6,"institutionHeld":0,"latestPrice":0.297,"eps":-7.996244,"divideRate":0,"volume":6273843,"delay":0,"ttmEps":-7.996244,"open":0.28,"prevYearClose":1.45,"prevWeekClose":0.505,"prevMonthClose":0.5199,"prevQuarterClose":0.5199,"fiveDayClose":0.505,"twentyDayClose":0.5774,"sixtyDayClose":1.01},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VBIO\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VBIO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VBIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VBIO","date":"2026-07-24","current":-0.037142,"percent":0.982759,"low":-0.392475,"twenty":-0.241361,"median":-0.149117,"eighty":-0.119839,"high":-0.067185,"avg":-0.181993,"sd":0.086772,"marketCap":915435},"quantilePoints":[{"date":"2026-04-30","current":-0.311197,"twenty":-0.324163,"median":-0.319301,"eighty":-0.314439,"marketCap":2762808},{"date":"2026-05-08","current":-0.33713,"twenty":-0.336482,"median":-0.327405,"eighty":-0.314439,"marketCap":2993043},{"date":"2026-05-15","current":-0.329149,"twenty":-0.341701,"median":-0.33551,"eighty":-0.327405,"marketCap":2922183},{"date":"2026-05-22","current":-0.203146,"twenty":-0.339301,"median":-0.327405,"eighty":-0.203206,"marketCap":2758322},{"date":"2026-05-29","current":-0.18116,"twenty":-0.338751,"median":-0.311197,"eighty":-0.201597,"marketCap":2459794},{"date":"2026-06-05","current":-0.173392,"twenty":-0.33713,"median":-0.203331,"eighty":-0.18116,"marketCap":2354321},{"date":"2026-06-12","current":-0.138668,"twenty":-0.333889,"median":-0.20236,"eighty":-0.175704,"marketCap":1882829},{"date":"2026-06-18","current":-0.131547,"twenty":-0.330097,"median":-0.198754,"eighty":-0.158647,"marketCap":1786145},{"date":"2026-06-26","current":-0.136114,"twenty":-0.327754,"median":-0.18598,"eighty":-0.135201,"marketCap":1848155},{"date":"2026-07-02","current":-0.122229,"twenty":-0.327405,"median":-0.179125,"eighty":-0.130362,"marketCap":1659627},{"date":"2026-07-10","current":-0.117868,"twenty":-0.31768,"median":-0.175704,"eighty":-0.126637,"marketCap":1600412},{"date":"2026-07-17","current":-0.115133,"twenty":-0.303417,"median":-0.165705,"eighty":-0.121795,"marketCap":1563282},{"date":"2026-07-24","current":-0.06742,"twenty":-0.241361,"median":-0.149117,"eighty":-0.119839,"marketCap":915435}],"updateTime":1785030921585},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VBIO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2653757314","title":"Ukraine Health Ministry Accepts Valion Bio Entolimod Dossier for Regulatory Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2653757314","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653757314?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:45","pubTimestamp":1784720719,"startTime":"0","endTime":"0","summary":"Ukraine health ministry accepts Valion Bio Entolimod dossier for regulatory reviewUkraine’s Ministry of Health accepted Valion Bio’s Entolimod dossier for formal review under its regulatory equivalenc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL7NrnTD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653975736","title":"Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2653975736","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653975736?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:45","pubTimestamp":1784720712,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nFWN43O0CO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VBIO","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653395757","title":"Valion Bio - Formal Review of Entolimod in Ukraine May be Completed in 45 to 60 Days","url":"https://stock-news.laohu8.com/highlight/detail?id=2653395757","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653395757?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:45","pubTimestamp":1784720712,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nFWN43O0CO:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VBIO","BK4139","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653106812","title":"Valion Bio Notifies Availability of Press Release on Entolimod Trial at Sheba Medical Center","url":"https://stock-news.laohu8.com/highlight/detail?id=2653106812","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653106812?lang=en_us&edition=fundamental","pubTime":"2026-07-21 01:29","pubTimestamp":1784568568,"startTime":"0","endTime":"0","summary":"Valion Bio notifies availability of press release on Entolimod trial at Sheba Medical CenterValion Bio disclosed a Sheba Medical Center-funded clinical trial to test Entolimod in cancer patients recei","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL16tvnB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VBIO","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651105134","title":"Valion Bio Advances Entolimod Program with Government Engagement, Manufacturing Scale-Up, Oncology Supportive Care Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2651105134","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651105134?lang=en_us&edition=fundamental","pubTime":"2026-07-14 20:35","pubTimestamp":1784032526,"startTime":"0","endTime":"0","summary":"Valion Bio  said Tuesday that it has advanced its Entolimod program through expanded US government engagement, a 200-fold manufacturing scale-up and plans to enter oncology supportive care.The company said it continues discussions with BARDA, NIAID, AFRRI and the Department of Defense on Acute Radiation Syndrome preparedness, while also engaging with Ukraine on potential stockpiling.Valion Bio said its unit, Velocity Bioworks, has completed a 200-fold manufacturing scale-up of Entolimod, equivalent to 1.3 million potential doses.The company said it also plans physician-sponsored studies evaluating Entolimod for chemotherapy-related neutropenia.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4082","VBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651108005","title":"Valion Bio reports continued development of Entolimod program","url":"https://stock-news.laohu8.com/highlight/detail?id=2651108005","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651108005?lang=en_us&edition=fundamental","pubTime":"2026-07-14 19:55","pubTimestamp":1784030136,"startTime":"0","endTime":"0","summary":"Valion Bio (VBIO) reported across a series of strategic initiatives for its Entolimod program – including continued engagement with U.S. government...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/valion-bio-reports-continued-development-of-entolimod-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/valion-bio-reports-continued-development-of-entolimod-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VBIO","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646480877","title":"Valion Bio Says Afrri, NIAID Design Murine Survival Protocol to Test Entolimod for Gi-ars","url":"https://stock-news.laohu8.com/highlight/detail?id=2646480877","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646480877?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:45","pubTimestamp":1782387922,"startTime":"0","endTime":"0","summary":"Valion Bio says AFRRI, NIAID design murine survival protocol to test Entolimod for GI-ARSValion Bio reported AFRRI and NIAID finalized a survival-efficacy protocol to evaluate Entolimod for gastrointe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL3fGSqM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VBIO","BK4082","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646877143","title":"Afrri/niaid Designs Proprietary Pbi-bm2.5 Protocol to Evaluate Valion Bio's (nasdaq: Vbio) Entolimod as the First and Only Treatment for Gi-ars","url":"https://stock-news.laohu8.com/highlight/detail?id=2646877143","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646877143?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:45","pubTimestamp":1782387918,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nFWN42W153:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VBIO","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644765086","title":"Valion Bio issues USD 250,000 Series B preferred shares, warrant to 3i in private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2644765086","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644765086?lang=en_us&edition=fundamental","pubTime":"2026-06-18 21:20","pubTimestamp":1781788848,"startTime":"0","endTime":"0","summary":"Valion Bio issued $250,000 of unregistered securities to 3i, LP in a private placement on June 17, 2026.Deal included 250 Series B Non-Voting Convertible Preferred shares priced at $1,000 each.Also issued a warrant for 156,026 common shares with an exercise price of $0.62 per share.Transaction fell under Section 4 and Rule 506 registration exemptions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL8MvSG1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VBIO","BK4139","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642281189","title":"Valion Bio confirms House panel directive to prioritize radiation, nuclear countermeasures","url":"https://stock-news.laohu8.com/highlight/detail?id=2642281189","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642281189?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:01","pubTimestamp":1781179303,"startTime":"0","endTime":"0","summary":"Valion Bio confirmed a U.S. House Armed Services Committee initiative in the FY27 NDAA process to prioritize radiation and nuclear medical countermeasures.The directive calls for a resources and fielding plan for countermeasures with both pre-exposure radioprotectant and post-exposure radiomitigant use.The update follows April and May 2026 briefings with senior Department of War officials and BARDA on Entolimod for acute radiation syndrome.Entolimod showed survival benefits as both a radioprotectant and radiomitigant in non-human primate studies under the FDA’s Animal Rule.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief on June 11, 2026, and is solely respo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL1XtMVV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636186239","title":"Valion Bio briefs Department of War, BARDA officials on Entolimod for radiation syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2636186239","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636186239?lang=en_us&edition=fundamental","pubTime":"2026-05-20 04:39","pubTimestamp":1779223163,"startTime":"0","endTime":"0","summary":"Valion Bio briefed senior U.S. Department of War officials alongside BARDA in a joint engagement on May 14, 2026, focused on Entolimod for acute radiation syndrome.Valion Bio highlighted interest in a field-deployable oral formulation as it advances Entolimod toward a Biologics License Application under the FDA’s Animal Rule, with about $35.6 million in prior U.S. government funding for the program.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL5SctnF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635273724","title":"Valion Bio’s Velocity Bioworks licenses LarmorBio’s BioScan-NMR platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2635273724","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635273724?lang=en_us&edition=fundamental","pubTime":"2026-05-15 06:26","pubTimestamp":1778797588,"startTime":"0","endTime":"0","summary":"Valion Bio’s (VBIO) wholly owned subsidiary, Velocity Bioworks, has entered into an exclusive commercial development and license agreement with Lar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/valion-bios-velocity-bioworks-licenses-larmorbios-bioscan-nmr-platform-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/valion-bios-velocity-bioworks-licenses-larmorbios-bioscan-nmr-platform-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VBIO","BK4082","BK4552","BK4127","NMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635573721","title":"Valion Bio Q1 net loss widens to $6.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635573721","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635573721?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:30","pubTimestamp":1778794252,"startTime":"0","endTime":"0","summary":"Valion Bio posted a net loss of USD 6.2 million for quarter ended March 31, 2026, widening from a net loss of USD 1.5 million a year earlier.Operating loss widened to USD 5.63 million as total operating expenses climbed to USD 5.63 million, led by research and development expense of USD 1.85 million and selling, general and administrative costs of USD 3.78 million.Cash and cash equivalents were USD 7.2 million at March 31, 2026, with cash used in operating activities of USD 5.01 million during the quarter.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL1LZJGW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635260877","title":"BRIEF-Valion Bio Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635260877","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635260877?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:52","pubTimestamp":1778791970,"startTime":"0","endTime":"0","summary":"BRIEF-Valion Bio Reports First Quarter 2026 Financial ResultsMay 14 (Reuters) - Valion Bio Inc VBIO.O:VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTSVALION BIO INC - Q1 2026 NET LOSS $2.23 PER","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA8JZZ6N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VBIO","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635723211","title":"Valion Bio Q1 EPS $(2.23) Up From $(2.52) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2635723211","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635723211?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:08","pubTimestamp":1778789328,"startTime":"0","endTime":"0","summary":"Valion Bio (NASDAQ:VBIO) reported quarterly losses of $(2.23) per share. This is a 11.51 percent increase over losses of $(2.52) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52579929/valion-bio-q1-eps-2-23-up-from-2-52-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Valion Bio Q1 EPS $(2.23) Up From $(2.52) YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPIQ","JEPQ","QYLG","QQQY","SQQQ","TQQY","PSQ","QQQ","BK4082","NQmain","NVIW.SI","QQQA","QID","TQQQ","FTEC","QQQJ","ONEQ","MNQmain","TECS","QDTE","QQQE","IYW","QQQM","VBIO",".IXIC","NDX","QLD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635726916","title":"Valion Bio Inc - Q1 2026 Net Loss $2.23 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2635726916","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635726916?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA8JZZ6N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VBIO","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634286749","title":"Valion Bio schedules first-quarter financial results release and conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2634286749","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634286749?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:06","pubTimestamp":1778501206,"startTime":"0","endTime":"0","summary":"Valion Bio will report first-quarter 2026 financial results May 14, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDLb3KspN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VBIO","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633382201","title":"Valion Bio subsidiary Velocity Bioworks opens biomanufacturing facility in San Antonio","url":"https://stock-news.laohu8.com/highlight/detail?id=2633382201","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633382201?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:11","pubTimestamp":1778069476,"startTime":"0","endTime":"0","summary":"Valion Bio opened Velocity Bioworks biomanufacturing facility in San Antonio, activating wholly owned subsidiary as core of vertically integrated domestic production for Entolimod.Velocity Bioworks employs about 45 staff, completed tech transfer of Entolimod process, started incremental scale-up to support GMP manufacturing.Facility positions unit to supply Entolimod for potential US Strategic National Stockpile use under FDA Animal Rule pathway.Velocity Bioworks also begins operating as CDMO for third-party biologics clients alongside internal manufacturing role.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL4zgtCf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633948376","title":"Valion Bio receives first study protocol under agreement with NIAID","url":"https://stock-news.laohu8.com/highlight/detail?id=2633948376","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633948376?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:15","pubTimestamp":1777983318,"startTime":"0","endTime":"0","summary":"Valion Bio (VBIO) announced it has received the first study protocol under its previously announced non-clinical evaluation agreement with the Nati...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/valion-bio-receives-first-study-protocol-under-agreement-with-niaid-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/valion-bio-receives-first-study-protocol-under-agreement-with-niaid-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VBIO","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633910577","title":"Valion Bio says NIAID funds up to $7 million Entolimod BLA-enabling studies under FDA Animal Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2633910577","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633910577?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:03","pubTimestamp":1777982591,"startTime":"0","endTime":"0","summary":"NIAID to fully fund up to USD 7 million of in vivo studies to support Entolimod BLA filing under FDA Animal Rule pathway.Program uses an FDA-precedent study protocol previously accepted for an acute radiation syndrome countermeasure, cutting design risk for BLA-enabling work.Studies to be run at Armed Forces Radiobiology Research Institute, with NIAID set to co-navigate FDA submission upon favorable results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via PR Newswire  on May 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL397Rwx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VBIO"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}]}}